Skip to main content

Table 4 OS comparisons stratified by major clinicopathological factors

From: Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy with lobaplatin and docetaxel improves survival for patients with peritoneal carcinomatosis from abdominal and pelvic malignancies

Variables Number Median OS (mo) 95 % CI (mo) P
Gender 0.955
 Male 41 22.7 6.2–39.2  
 Female 59 24.2 14.2–34.2  
Age (year) 0.608
 <60 71 22.7 13.4–32.0  
 ≥60 29 25.9 7.0–44.8  
Primary tumor 0.000
 Carcinoma of the stomach 30 15.7 10.8–20.6  
 Carcinoma of the colorectum 41 14.9 7.9–21.9  
 Pseudomyxoma peritonei 13 Not reached Not reached  
 Carcinoma of ovary and primary peritoneum 16 34.6 22.1–47.1  
Neoadjuvant chemotherapy 0.128
 No 53 31.2 18.4–44.0  
 Yes 47 20.7 11.6–29.8  
PC timing 0.086
 Synchronous 80 27.5 18.1–36.9  
 Metachronous 20 13.2 10.6–15.8  
PCI scores 0.000
 ≤20 44 46.1 10.7–81.5  
 >20 56 16.3 8.6–24.0  
CC scores 0.000
 0–1 63 42.9 28.3–57.5  
 2–3 37 13.6 10.6–15.6  
Postoperative chemotherapy cycles 0.000
 <6 49 14.1 9.6–18.6  
 ≥6 51 31.9 24.1–39.7  
SAE 0.007
 No 86 31.2 20.5–41.9  
 Yes 14 12.2 9.5–15.0  
Ascites     0.095
 ≤1000 mL 63 24.2 13.5–34.9  
 >1000 mL 37 21.2 4.8–37.7  
  1. In the original surgery calculation
  2. OS overall survival, mo months